These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [CHARM study--new strategy for the treatment of heart failure].
    Author: Hasegawa H, Komuro I.
    Journal: Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833.
    Abstract:
    CHARM (candesartan in heart failure assessment of reduction in mortality and morbidity) is the largest trial program in chronic heart failure. To elucidate the effect of candesartan on various symptomatic chronic heart failure, the randomization protocol was used in 3 separate trial arms: 2028 with LVEF < 40% who could not tolerate ACE inhibitors; 2548 with LVEF < 40% who already were taking ACE inhibitor; and 3023 with LVEF > 40%. The overall mortality benefit of the candesartan was better than placebo. In the 2 trial arms that included patients with LVEF < 40%, incidence of the mortality and hospitalization was significantly lower with candesartan than with placebo. It may be the new evidence of angiotensin receptor blocker on 3 other types of heart failure.
    [Abstract] [Full Text] [Related] [New Search]